Acarix, developer of the CADScor®System for Coronary Artery Disease (CAD) risk assessment, today announced the appointment of a highly experienced marketing expert, Johanne Louise Brændgaard, as a member of the board of directors.
“We are delighted to welcome Johanne as member of the board. She has wide-ranging experience from the medtech sector in setting product, marketing and sales strategies specifically for the important European, US and APAC markets and an impressive network from the cardiovascular disease area. We expect that she will contribute immensely to achieving our goals with the accelerated market expansion activities.” said Dr. Werner Braun, Chairman of the Board.
Johanne Louise Brændgaard has 13 years of experience from global sales, marketing and product management within the Medtech industry through positions in Cook Medical and Getinge. Johanne has a Master's degree in International Business Economics from Aalborg University in Denmark.
Dr. Werner Braun, Chairman of the Board, E-mail firstname.lastname@example.org, Phone: +49 151 70 131 343
Notes to editors:
Acarix was established in 2009, and since 2010 investors Sunstone Life Science Ventures (DK) and SEED Capital (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First North Premier in 2016 and has attracted a highly-experienced management team. The Acarix CADScor®System combines ultra-sensitive acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a portable device to provide a patientspecific score to non-invasively assess the risk for Coronary Artery Disease (CAD) in less than 10 minutes. The system has been clinically validated.
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.